# Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients

> **NCT05944458** · PHASE4 · COMPLETED · sponsor: **Helwan University** · enrollment: 250 (actual)

## Conditions studied

- Linezolid
- Antioxidant
- Thrombocytopenia
- Critical Illness
- ICU

## Interventions

- **DRUG:** N acetyl cysteine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05944458
- **Lead sponsor:** Helwan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2025-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05944458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05944458, "Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05944458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*